Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial

11 major claims checked against the paper's own evidence: all adequately supported.

7 copyedit issues flagged: mostly consistency, grammar, clarity.

Checked 24 references: 19 verified — 5 unresolved.

1 data/code link checked; 1 live.

Ready after minor to moderate revision. The data-availability statement must be upgraded to a concrete managed-access repository before submission; this is the single most consequential gap. The other issues (missing manufacturer, exact p-values, ethics committee details in main text, and copyedits) are routine fixes that can be completed in a few hours. The paper's core scientific contribution is strong and not undermined by these reporting gaps.

1. 1.
   HIGHdata code

   Replace the vague 'on request' data-availability statement with a concrete managed-access platform (e.g., Vivli, YODA, or ClinicalStudyDataRequest) including access conditions and timeline, and cite the repository name and expected availability date in the Data availability section.

   Journals increasingly require a specific data-sharing platform; a vague statement risks rejection and undermines reproducibility.
2. 2.
   HIGHdata code

   Deposit the deidentified individual participant data in an appropriate repository (e.g., Vivli, ClinicalTrials.gov results database) and, if possible, also share the SAS analysis scripts in a public code repository (e.g., GitHub, Zenodo) with a DOI.

   Absent a data or code deposit, the study's reproducibility is not verifiable, and this is a common reason for editorial rejection.
3. 3.
   HIGHrigor

   For each of the 5 references that our check could not locate in any registry (see citation flagged list: 'Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection', 'Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries', 'Hepatitis B Vaccine (Recombinant) (PREHEVBRIO®) [Package Insert]', 'Efficacy and safety of elebsiran... follow-up results from ongoing... ENSURE study', 'Chronic hepatitis B virus infected participants responding to prior BRII-179 treatment...'), verify that the reference exists and correct the bibliographic details if needed, or remove it if it cannot be verified.

   Unresolved references in a registry check may indicate a citation error or, in rare cases, fabrication; journals routinely check references and will return the manuscript.
4. 4.
   HIGHreporting

   In the Methods section (Study design), add the manufacturer/source for elebsiran (Brii Biosciences) and PEG-IFNα (e.g., Roche).

   Naming the manufacturer is standard for clinical trial interventions and is expected by reviewers and editors.
5. 5.
   HIGHreporting

   In the Methods section, provide a brief rationale for the open-label design (e.g., practical infeasibility of double-blinding due to different injection schedules, injection frequency, or safety monitoring needs).

   An open-label design without justification raises concerns about bias; a one-sentence explanation resolves the issue.
6. 6.
   HIGHreporting

   In the Methods section (Statistical methods), supplement the Bayesian sample size justification with the assumed effect size, power, and alpha level, or clearly state that these were not pre-specified and explain why the Bayesian approach was chosen.

   A sample size justification that omits power, effect size, and alpha is incomplete per standard reporting guidelines (CONSORT); adding these strengthens the manuscript.
7. 7.
   HIGHstatistics

   In the Results (Key secondary efficacy outcomes) and Extended Data Table 3, replace the threshold 'P < 0.05' with exact p-values (e.g., 'P = 0.023') for all MMRM analyses.

   Threshold-only p-values are insufficient for transparency; exact values enable readers to assess significance precisely and are required by many journals.
8. 8.
   HIGHethics

   Add the specific ethics committee names and approval numbers/protocol numbers to the main manuscript (e.g., in the Methods, Study design section), rather than only in the Supplementary Information.

   Main-text reporting of ethics committee details is standard; deferring to supplementary material is a minor but avoidable reporting gap.
9. 9.
   MEDIUMcopyedit

   Fix typo: in the Data availability section, change 'ClinicalTrial.gov' to 'ClinicalTrials.gov' (standard capitalization).

   Correct capitalization improves professionalism and accuracy.
10. 10.
    MEDIUMcopyedit

    Fix spelling inconsistency: in the Competing interests section, ensure 'Barthinus Biotherapeutics' reads consistently as 'Barinthus Biotherapeutics' throughout.

    Spelling inconsistencies across competing interest statements can appear careless to reviewers.
11. 11.
    MEDIUMcopyedit

    In the Methods, Study design section, change 'NRTI as background therapy' to 'NRTIs as background therapy' for grammatical consistency.

    Minor grammar fix to standardize pluralization of drug classes.
12. 12.
    MEDIUMcopyedit

    In the Methods, Statistical methods section, revise the sentence 'The post probability of true response rate >0.15 is more than 90%.' to 'The posterior probability that the true response rate exceeds 15% is >90%.' for clarity.

    The original wording is ambiguous; the suggested revision accurately reflects Bayesian terminology.
13. 13.
    MEDIUMcopyedit

    In the Discussion, paragraph 1, consider splitting the long sentence beginning 'The results of this study provide important insights...' into two sentences for improved readability.

    A long, multi-clause sentence can be hard to parse; splitting improves clarity.
14. 14.
    MEDIUMcopyedit

    In the Data availability section, remove the spurious phrase 'are provided with this paper' at the end of the sentence about the contact person.

    The phrase appears to be a template remnant and is grammatically incorrect.
15. 15.
    LOWcopyedit

    Ensure consistent capitalization of 'Part I' and 'Part II' (with capital P) throughout the text; the abstract and methods use both lowercase and uppercase.

    Minor consistency fix for a polished manuscript.